Treatment of VAP Without Antimicrobial Resistance Risk Factors in Low-Resistance ICUs
Not every case of ventilator-associated pneumonia requires broad-spectrum combination antibiotics. When the patient has no risk factors for antimicrobial resistance and the ICU's local resistance data remain below defined thresholds, a targeted, streamlined empiric approach is appropriate.
The patient has suspected VAP, carries no identified risk factors for antimicrobial resistance, and is treated in an ICU where fewer than 10%–20% of Staphylococcus aureus isolates are methicillin resistant and 10% or fewer gram-negative isolates are resistant to the antibiotic being considered for monotherapy.
The protocol calls for empiric intravenous monotherapy — a single agent active against both methicillin-sensitive S. aureus and P. aeruginosa — without adding MRSA-targeted coverage. The full structured protocol specifies which agents qualify and the recommended course length.
References
DOI: 10.1093/cid/ciw353
- We suggest including an agent active against MSSA (and not MRSA) for the empiric treatment of suspected VAP in patients without risk factors for antimicrobial resistance, who are being treated in ICUs where <10%–20% of S. aureus isolates are methicillin resistant (weak recommendation, very low-quality evidence).
- We suggest prescribing one antibiotic active against P. aeruginosa for the empiric treatment of suspected VAP in patients without risk factors for antimicrobial resistance who are being treated in ICUs where ≤10% of gram-negative isolates are resistant to the agent being considered for monotherapy (weak recommendation, low-quality evidence).
- When empiric coverage for MSSA (and not MRSA) is indicated, we suggest a regimen including piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem (weak recommendation, very low-quality evidence).
- For patients with VAP, we recommend a 7-day course of antimicrobial therapy rather than a longer duration (strong recommendation, moderate-quality evidence).